MX386250B - Formulaciones novedosas. - Google Patents

Formulaciones novedosas.

Info

Publication number
MX386250B
MX386250B MX2016006012A MX2016006012A MX386250B MX 386250 B MX386250 B MX 386250B MX 2016006012 A MX2016006012 A MX 2016006012A MX 2016006012 A MX2016006012 A MX 2016006012A MX 386250 B MX386250 B MX 386250B
Authority
MX
Mexico
Prior art keywords
novel formulations
formulations
novel
carbamoyl
trifluoromethyl
Prior art date
Application number
MX2016006012A
Other languages
English (en)
Spanish (es)
Other versions
MX2016006012A (es
Inventor
George William Farr
Marc F Pelletier
Paul Robert Mcguirk
Original Assignee
Aeromics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeromics Inc filed Critical Aeromics Inc
Publication of MX2016006012A publication Critical patent/MX2016006012A/es
Publication of MX386250B publication Critical patent/MX386250B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
MX2016006012A 2013-11-06 2014-11-06 Formulaciones novedosas. MX386250B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361900919P 2013-11-06 2013-11-06
US201361900878P 2013-11-06 2013-11-06
US201361900946P 2013-11-06 2013-11-06
PCT/US2014/064441 WO2015069956A2 (en) 2013-11-06 2014-11-06 Novel formulations

Publications (2)

Publication Number Publication Date
MX2016006012A MX2016006012A (es) 2016-12-09
MX386250B true MX386250B (es) 2025-03-18

Family

ID=53042097

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006012A MX386250B (es) 2013-11-06 2014-11-06 Formulaciones novedosas.
MX2021008629A MX2021008629A (es) 2013-11-06 2016-05-06 Formulaciones novedosas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021008629A MX2021008629A (es) 2013-11-06 2016-05-06 Formulaciones novedosas.

Country Status (14)

Country Link
US (8) US9827253B2 (enExample)
EP (3) EP3065729A4 (enExample)
JP (4) JP6535338B2 (enExample)
KR (1) KR20160079109A (enExample)
CN (3) CN112402434A (enExample)
AU (2) AU2014346682B2 (enExample)
CA (1) CA2929821A1 (enExample)
ES (1) ES2834131T3 (enExample)
HK (1) HK1224228A1 (enExample)
IL (1) IL245420B (enExample)
MX (2) MX386250B (enExample)
RU (1) RU2691951C2 (enExample)
SG (1) SG11201604153UA (enExample)
WO (3) WO2015069956A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013169939A2 (en) 2012-05-08 2013-11-14 Aeromics, Llc New methods
KR20160079109A (ko) 2013-11-06 2016-07-05 에어로믹스, 인코포레이티드 새로운 조성물
CN115093443A (zh) * 2016-05-13 2022-09-23 埃罗米克斯公司 晶体
JP2021023226A (ja) * 2019-08-06 2021-02-22 学校法人慶應義塾 アクアポリン活性調節剤候補のハイスループットスクリーニング方法
CN110790787B (zh) * 2019-11-12 2022-06-14 广东药科大学 一类水溶性前药、其制备方法及其作为药物的用途
JP2023536509A (ja) * 2020-08-05 2023-08-25 ジャンスー・シムセレ・ファーマシューティカル・カンパニー・リミテッド アクアポリン阻害剤の医薬組成物およびその製造方法
CN117105810B (zh) * 2023-10-23 2024-02-09 中国农业大学 一种具有广谱抗菌活性的化合物及其抗菌组合物
CN118178653A (zh) * 2024-03-22 2024-06-14 山东第一医科大学附属省立医院(山东省立医院) 跨膜水交换蛋白aqp4抑制剂在制备抗肿瘤药物上的应用

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE615511A (enExample) 1961-03-25
NL292958A (enExample) 1962-05-29 1900-01-01
GB8809205D0 (en) 1988-04-19 1988-05-25 Nye P C G Treatment of oedema
US5137871A (en) 1989-07-28 1992-08-11 Regents Of The University Of California Treatment to reduce edema for brain and musculature injuries
DE4010536A1 (de) * 1990-04-02 1991-10-10 Boehringer Mannheim Gmbh Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure
DE4113820A1 (de) 1991-04-27 1992-10-29 Boehringer Mannheim Gmbh Verwendung von torasemid zur behandlung von hirnoedemen
US5486530A (en) 1991-04-27 1996-01-23 Boehringer Mannheim Gmbh Use of torasemide for the treatment of brain oedemas
US5741671A (en) 1991-12-12 1998-04-21 The Johns Hopkins University Isolation cloning and expression of transmembrane water channel aquaporin 1(AQP1)
US5858702A (en) 1991-12-13 1999-01-12 The Johns Hopkins University Isolation, cloning and expression of transmembrane water channel Aquaporin 5 (AQP5)
US5519035A (en) 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia
US20060167110A1 (en) 1995-01-13 2006-07-27 Blume Cherly D Methods for treating cerebrovascular disease by administering desmethylselegiline
CA2243643A1 (en) 1996-11-18 1998-05-28 Susan Haas Methods and compositions for inducing oral tolerance in mammals
EP1005347A4 (en) 1997-08-06 2002-08-28 Smithkline Beecham Corp ANTAGONISTS OF THE RECEPTORS OF THE MONOCYTE MACROPHAGE FOR USE IN TREATING CARDIOVASCULAR DISEASES
US5905090A (en) 1998-04-29 1999-05-18 Italfarmaco S.P.A. Analogues of the active metabolite of leflunomide
CO5180581A1 (es) * 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
US6500809B1 (en) 1999-11-12 2002-12-31 Neuron Therapeutics, Inc. Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith
ES2211460T3 (es) 1999-12-10 2004-07-16 Pfizer Inc. Compuestos de 1,4-dihidropiridina sustituidos con un heteroalrilo de 5 miembros como antagonistas de la bradiquinina.
UA82827C2 (en) 2000-12-18 2008-05-26 Inhibitors against the production and release of inflammatory cytokines
US7872048B2 (en) 2004-09-18 2011-01-18 University Of Maryland, Baltimore Methods for treating spinal cord injury with a compound that inhibits a NCCa-ATP channel
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
PT2438913T (pt) 2002-03-20 2020-05-27 Us Veterans Affairs Canal de catiões não seletivos em células neurais e compostos que bloqueiam o canal para utilização no tratamento de edema cerebral
TW200410671A (en) 2002-06-05 2004-07-01 Inst Med Molecular Design Inc Medicines for inhibiting the activation of AP-1
AU2003242131A1 (en) 2002-06-05 2003-12-22 Institute Of Medicinal Molecular Design, Inc. Immunity-related protein kinase inhibitors
CN101103977A (zh) 2002-06-05 2008-01-16 株式会社医药分子设计研究所 糖尿病治疗药
CN1658855B (zh) 2002-06-06 2010-04-28 株式会社医药分子设计研究所 O-取代羟基芳基衍生物
CN1658872B (zh) 2002-06-06 2010-09-22 株式会社医药分子设计研究所 抗过敏药
EP1535610A4 (en) 2002-06-10 2008-12-31 Inst Med Molecular Design Inc THERAPEUTIC CANCER
EA010470B1 (ru) * 2002-06-10 2008-08-29 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. ИНГИБИТОРЫ АКТИВАЦИИ NF-kB
EA011707B1 (ru) 2002-06-11 2009-04-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения нейродегенеративных заболеваний
WO2004006858A2 (en) 2002-07-15 2004-01-22 Myriad Genetics, Inc Compounds, compositions, and methods employing same
ES2398460T3 (es) 2003-02-06 2013-03-19 Queen's University Of Belfast Péptido antagonista del receptor B2 de bradiquinina proveniente de la piel de un anfibio
CA2523740C (en) 2003-05-01 2012-05-15 Innogene Kalbiotech Pte Ltd Lactate containing pharmaceutical composition and uses thereof
JPWO2005007151A1 (ja) 2003-07-16 2006-08-31 株式会社医薬分子設計研究所 皮膚色素沈着の治療剤
EP1680411A2 (en) 2003-10-08 2006-07-19 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups
US8467876B2 (en) 2003-10-15 2013-06-18 Rmx, Llc Breathing disorder detection and therapy delivery device and method
WO2005039556A1 (ja) 2003-10-29 2005-05-06 Institute Of Medicinal Molecular Design. Inc. 血行再建術後の再狭窄又は再閉塞の治療及び／又は予防のための医薬
US7378509B2 (en) 2003-12-02 2008-05-27 Anesiva, Inc. NF-kappaB oligonucleotide decoy molecules
EP2359832A3 (en) 2004-09-18 2011-11-23 University of Maryland, Baltimore Therapeutic agents targeting the NCCA-ATP channel and methods of use thereof
US7601745B2 (en) 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
KR20070111475A (ko) 2005-01-04 2007-11-21 노파르티스 아게 만성 변비 환자에서 테가세로드의 효능을 확인하기 위한바이오마커
TWI462745B (zh) * 2005-04-28 2014-12-01 Takeda Pharmaceutical 安定的乳化組成物
WO2007084464A2 (en) 2006-01-17 2007-07-26 The University Of North Carolina At Chapel Hill Water channel blockers and methods of use thereof
JP4273235B2 (ja) * 2006-06-01 2009-06-03 国立大学法人 新潟大学 アクアポリン４阻害薬
CA2654000A1 (en) 2006-06-06 2008-05-22 Genentech, Inc. Anti-dll4 antibodies and methods using same
US20080014196A1 (en) 2006-06-06 2008-01-17 Genentech, Inc. Compositions and methods for modulating vascular development
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
WO2008046014A1 (en) 2006-10-12 2008-04-17 Remedy Pharmaceuticals, Inc. Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
WO2008052190A2 (en) 2006-10-26 2008-05-02 Flynn Gary A Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
US9316633B2 (en) 2006-11-16 2016-04-19 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
WO2008067373A2 (en) 2006-11-28 2008-06-05 Alcon Research, Ltd. RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS
US20080214486A1 (en) 2006-11-28 2008-09-04 Alcon Manufacturing, Ltd. RNAi-MEDIATED INHIBITION OF AQUAPORIN 4 FOR TREATMENT OF IOP-RELATED CONDITIONS
EP3103451A1 (en) 2007-01-12 2016-12-14 University of Maryland, Baltimore Targetting ncca-atp channel for organ protection following ischemic episode
BRPI0806774A2 (pt) 2007-01-16 2011-09-13 Ipintl Llc composição para tratamento de sìndrome metabólica
US20120183600A1 (en) * 2007-01-16 2012-07-19 Chien-Hung Chen Novel composition for treating metabolic syndrome and other conditions
EP2114160B1 (en) 2007-02-09 2016-11-16 University of Maryland, Baltimore Antagonists of a non-selective cation channel in neural cells
AU2008216612B2 (en) 2007-02-17 2014-12-04 President And Fellows Of Harvard College Compositions and method for tissue preservation
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
CA2974689C (en) 2007-06-22 2020-02-25 The United States Of America As Represented By The Department Of Veters Affairs Inhibitors of ncca-atp channels for therapy
EP2178531A4 (en) * 2007-07-02 2012-01-11 Yu Ming METHODS AND COMPOSITIONS, TARGETS FOR COMBINED CANCER TREATMENTS
US20090239868A1 (en) 2007-10-23 2009-09-24 Institute Of Medical Molecular Design, Inc. Inhibitor of pai-1 production
BRPI0816560A2 (pt) 2007-10-23 2015-09-01 Inst Med Molecular Design Inc Método de inibição de produção de pai-1 método para prevenção ou melhora de uma doença causada por uma super-produção de pai-1"
US8277845B2 (en) 2007-12-04 2012-10-02 Remedy Pharmaceuticals, Inc. Formulations and methods for lyophilization and lyophilates provided thereby
GB0724340D0 (en) 2007-12-13 2008-01-30 Univ Dundee Novel Therapeutic Agents
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20110034560A1 (en) 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
US8211882B2 (en) 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
WO2009139925A1 (en) 2008-05-16 2009-11-19 Panacea Pharmaceuticals, Inc. Methods for the treatment of brain edema
WO2010033560A2 (en) 2008-09-16 2010-03-25 University Of Maryland, Baltimore Sur1 inhibitors for therapy
WO2010048273A2 (en) 2008-10-21 2010-04-29 President And Fellows Of Harvard College Methods and compounds for treatment of neurodegenerative disorders
GB0823366D0 (en) 2008-12-22 2009-01-28 Uni I Oslo Synthesis
WO2010079406A1 (en) 2009-01-12 2010-07-15 Purapharm International (Hk) Limited Compounds and uses thereof for treating inflammation and modulating immune responses
WO2010096627A1 (en) 2009-02-20 2010-08-26 Lisanti Michael P Therapeutics and methods for treating neoplastic diseases comprising determining the level of caveolin-1 and/or caveolin-2 in a stromal cell sample
BR112012022654A2 (pt) 2010-03-10 2016-11-01 Univ Florida modulação de aquaporinas com relaxina
EP2595633A4 (en) 2010-07-19 2014-01-22 Remedy Pharmaceuticals Inc METHOD FOR INTRAVENOUS ADMINISTRATION OF GLYBURID AND OTHER MEDICAMENTS
EP2598145A1 (en) * 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Pharmaceutical composition for treatment of respiratory and inflammatory diseases
US20110052678A1 (en) 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
WO2012125749A2 (en) 2011-03-14 2012-09-20 Io Therapeutics, Inc. INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARα SELECTIVE AGONISTS
LT2717883T (lt) * 2011-05-02 2017-04-25 Stichting Vumc Apsauga nuo endotelio barjero disfunkcijos, slopinant su abl susijusio geno (arg) tirozino kinazę
RU2461375C1 (ru) * 2011-05-19 2012-09-20 Учреждение Российской академии медицинских наук Научно-исследовательский институт онкологии Сибирского отделения Российской академии медицинских наук (НИИ онкологии СО РАМН) Способ комбинированного лечения больных местно-распространенным раком желудка
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
EP2844345B1 (en) 2012-05-04 2022-08-03 The United States of America, as Represented by The Secretary, Department of Health and Human Services Modulators of the relaxin receptor 1
WO2013169939A2 (en) * 2012-05-08 2013-11-14 Aeromics, Llc New methods
WO2015037659A1 (ja) 2013-09-13 2015-03-19 株式会社医薬分子設計研究所 水溶液製剤及びその製造方法
KR20160079109A (ko) 2013-11-06 2016-07-05 에어로믹스, 인코포레이티드 새로운 조성물
SMT201800521T1 (it) 2013-12-13 2018-11-09 Vertex Pharma Profarmaci di piridonammidi utili come modulatori di canali del sodio
CA2966950A1 (en) 2014-11-13 2016-05-19 Aeromics, Inc. Novel methods
WO2016196113A1 (en) 2015-05-29 2016-12-08 University Of Maryland, Baltimore Methods of reducing or preventing intimal damage caused by mechanical stimulation of endothelial cells
BR112018006925A2 (pt) 2015-10-07 2018-10-16 Biogen Chesapeake Llc métodos de tratamento de lesões ou patologias associadas com um edema do snc
CN115093443A (zh) 2016-05-13 2022-09-23 埃罗米克斯公司 晶体
CA3032294C (en) 2016-07-29 2025-03-11 Biogen Chesapeake Llc MEDICAL TREATMENT METHODS WITH SUR1-TRPM4 CHANNEL INHIBITORS
JP2023536509A (ja) 2020-08-05 2023-08-25 ジャンスー・シムセレ・ファーマシューティカル・カンパニー・リミテッド アクアポリン阻害剤の医薬組成物およびその製造方法

Also Published As

Publication number Publication date
BR112016010338A2 (pt) 2017-08-08
MX2021008629A (es) 2021-08-19
CN112402434A (zh) 2021-02-26
EP3065729A4 (en) 2017-05-31
HK1224228A1 (zh) 2017-08-18
MX2016006012A (es) 2016-12-09
CN112370456A (zh) 2021-02-19
AU2020203697A1 (en) 2020-06-25
US20160264604A1 (en) 2016-09-15
AU2014346682B2 (en) 2020-03-12
US20240299425A1 (en) 2024-09-12
RU2016121850A (ru) 2017-12-08
JP6957557B2 (ja) 2021-11-02
JP2016536370A (ja) 2016-11-24
RU2016121850A3 (enExample) 2018-08-08
ES2834131T3 (es) 2021-06-16
US10258636B2 (en) 2019-04-16
EP3065727A4 (en) 2017-05-31
CN106163506A (zh) 2016-11-23
US20220143048A1 (en) 2022-05-12
WO2015069956A3 (en) 2015-11-12
EP3065728A4 (en) 2017-06-07
US10894055B2 (en) 2021-01-19
JP2016535787A (ja) 2016-11-17
CA2929821A1 (en) 2015-05-14
US20210275549A1 (en) 2021-09-09
US20160346302A1 (en) 2016-12-01
RU2691951C2 (ru) 2019-06-19
US20200297740A1 (en) 2020-09-24
IL245420A0 (en) 2016-06-30
EP3065728A1 (en) 2016-09-14
AU2014346682A1 (en) 2016-06-09
EP3065727B1 (en) 2020-08-26
US11801254B2 (en) 2023-10-31
US20190307779A1 (en) 2019-10-10
WO2015069948A1 (en) 2015-05-14
IL245420B (en) 2020-10-29
JP2019163314A (ja) 2019-09-26
WO2015069961A1 (en) 2015-05-14
SG11201604153UA (en) 2016-07-28
US20180169118A1 (en) 2018-06-21
EP3065729A2 (en) 2016-09-14
JP6535338B2 (ja) 2019-06-26
US9949991B2 (en) 2018-04-24
US9827253B2 (en) 2017-11-28
US12213987B2 (en) 2025-02-04
KR20160079109A (ko) 2016-07-05
JP2022003084A (ja) 2022-01-11
WO2015069956A2 (en) 2015-05-14
EP3065727A1 (en) 2016-09-14
US20160279155A1 (en) 2016-09-29
US11071744B2 (en) 2021-07-27

Similar Documents

Publication Publication Date Title
MX386250B (es) Formulaciones novedosas.
UY36481A (es) Compuestos de picolinamida con actividad fúngicida
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
UY34811A (es) Compuestos y composiciones para inhibir la actividad de la abl1, abl2 y bcr-abl1
CO2017006855A2 (es) Picolinamidas con actividad fungicida
UY36489A (es) Uso de compuestos de picolinamida con actividad fuingicida
UY36497A (es) Uso de compuestos de picolinamida con actividad fungicida
UY34651A (es) ?formas de dosificación de liberación inmediata resistentes a la manipulación, procesos para prepararlas, métodos y usos de las mismas?..
UY36499A (es) Uso de picolinamidas como fungicidas
UY34778A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA HETEROCÍCLICOS SUSTITUÍDOS?.
CR20140200A (es) Formas solidas de 3-(5-amino-2-metil-4-oxo-ah-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
UY34302A (es) COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2- AMINA
UY35661A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que lo s contienen
CO2018001756A2 (es) Concentrados en suspensión aceitosa con baja separación gravimétrica y baja viscosidad
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
CR20160044S (es) Dispensador de jabon
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
UY34725A (es) Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos.
EA201590688A1 (ru) Производные n-проп-2-инилкарбоксамида и их применение в качестве антагонистов trpa1
UY36500A (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
UY33976A (es) Derivados de pirazolo-pirimidina.
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
MX2016002217A (es) Compuestos con actividad pesticida.